Duloxetine versus placebo in the treatment of stress urinary incontinence. - Test2 - elhamkhani - TriplyDB

Duloxetine versus placebo in the treatment of stress urinary incontinence.

Duloxetine versus placebo in the treatment of stress urinary incontinence.

http://www.wikidata.org/entity/Q44062087

about

Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults Neurophysiology of lower urinary tract function and dysfunction Duloxetine in the treatment of stress urinary incontinence Stress urinary incontinence in women.Duloxetine compared with placebo for treating women with symptoms of overactive bladder.Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trial Stress incontinence.Neural control of the lower urinary tract: peripheral and spinal mechanisms Urinary incontinence in the elderly: part 3 of a series of articles on incontinence Neural control of the female urethral and anal rhabdosphincters and pelvic floor muscles.Alpha2-adrenoceptor blockade potentiates the effect of duloxetine on sneeze induced urethral continence reflex in rats.The role of duloxetine in stress urinary incontinence: a systematic review and meta-analysis.Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports.Urinary Side Effects of Duloxetine in the Treatment of Depression and Stress Urinary Incontinence Duloxetine in the treatment of major psychiatric and neuropathic disorders.Duloxetine: a serotonin-noradrenaline re-uptake inhibitor for the treatment of stress urinary incontinence.Lower urinary tract disease: what are we trying to treat and in whom?Nursing management of stress urinary incontinence in women.Current management of stress urinary incontinence.Clinical practice guidelines for the initial management of urinary incontinence in women: a European-focused review.Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers.Clinical practice guidelines on the initial assessment and treatment of urinary incontinence in women: a US focused review.Duloxetine: a new approach for treating stress urinary incontinence.Neurobiology of stress urinary incontinence: new insights and implications for treatment.Safety and adverse event profile of duloxetine.Coining a new term-Urovesicology: advancing towards a mechanistic understanding of bladder symptoms.Duloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression.Observational study on safety and tolerability of duloxetine in the treatment of female stress urinary incontinence in German routine practice.An overview of stress urinary incontinence treatment in women.The treatment of urinary incontinence with Duloxetine.Urodynamic leak point pressures weakly correlate with subjective urinary incontinence severity.Current issues in the management of female urinary incontinence.Update on duloxetine for the management of stress urinary incontinence.Stem cells for stress urinary incontinence: the adipose promise.The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports.Inhibition of bladder overactivity by duloxetine in combination with foot stimulation or WAY-100635 treatment in cats.Treatment of mixed urinary incontinence.Duloxetine Treatment of Stress Urinary Incontinence in Women Does Not Induce Mania or Hypomania.Neurophysiology and therapeutic receptor targets for stress urinary incontinence.Management of mixed urinary incontinence.

P2860

Q24246568-8E47C967-278D-4FD7-B217-53503428A50F Q24550931-4FF639F6-FB06-4E83-ADDE-9D725CB557FA Q24680252-F8C19353-44E3-4A62-8783-7617FB24D627 Q30433747-201D2050-D0F3-4DC0-9D64-2192ED56187B Q30443662-F5756BF9-049A-46E6-B9CD-A8E277B4A5F6 Q33316575-3C3432DA-636E-464D-A5C5-8B6846F3B85F Q34010677-F8984051-AAC1-453C-9C5B-54341F4A34F2 Q34020395-90CF92D9-1F70-4F7E-B032-788B059C8C6E Q34078299-AB7F49EA-481C-4BA7-94CB-BCEBE007FBFC Q34085595-F4243171-3F79-493B-A3EB-C192FF9CE8CB Q34158357-7C42F9D7-3C84-4FAD-8A76-10A8AF3BA12B Q34333544-BC73FCDB-8395-4139-B86F-A14D60052BC0 Q34552333-291A78F4-6FFD-4A12-9FD9-FFB90164372C Q34769139-45034CC3-E292-481E-8035-0D3B42DB6A6A Q34770302-127FA65F-C847-4340-8681-863CB51C31D3 Q35207634-25C8887A-4BFD-4B39-B166-41180EEB3552 Q35545715-BE38E2FE-9E4F-4595-AB57-481873FF4BBC Q35668828-BFF13D9A-33F3-481E-B902-7113FBB63716 Q35771615-9E4DE659-A3AF-4BC3-8DA3-B090F9DCA490 Q35771620-9E12681D-C01E-46EF-A6B9-D01E89262B4F Q35826128-A746E959-76FD-4830-BE9A-567965127CCF Q35859633-4D250880-812B-4407-9DBB-A474BB651480 Q35859638-C7B301DC-E299-401F-A731-F42B13AE9B07 Q36290129-6BA62A39-7A0D-4C34-83EE-5DFABA726C13 Q36299961-C7865709-B848-4AC7-B6A5-D77CC59480D0 Q36463541-BF64018E-C27C-47DA-8EBA-EDE8355F02A2 Q36489025-0BD83557-391C-4A2F-A596-231791EEC3CB Q36729973-6D392047-BC68-48C7-BBDA-0015F1DCC5E4 Q36921864-B12C62D1-127B-4BCE-A576-1D7B2D0083CD Q37130272-91773DC7-5534-4802-AA6D-9E3805C9140D Q37172606-C26DF7D0-713C-4684-8DF5-B0B66319C3EA Q37192368-70D09B9E-28E4-433E-A984-36E82044A2B2 Q37199879-FA4F7253-B34A-4DA8-B790-F8DBFF3D3495 Q37334953-78597850-D7BF-4082-8EBA-663BB8974DBF Q37360532-0A965D63-4C7A-4C7D-86BE-6CB0155954CE Q37440147-F846517A-626F-42CE-9D25-409F5A9CA230 Q37579064-196A1862-08D9-437D-9D4B-E0AEF7C159DE Q37708622-36B49425-1D5A-4E0E-9FA8-2D1FDF675631 Q37992131-471D46F8-1911-4A83-86AE-7665985F667D Q38039168-5B36499F-92E9-4EED-994F-39AF7C4CDE7E

P2860

Duloxetine versus placebo in the treatment of stress urinary incontinence.

http://www.wikidata.org/entity/Q44062087

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh

2002年學術文章

@zh-hant

name

Duloxetine versus placebo in the treatment of stress urinary incontinence.

@en

Duloxetine versus placebo in the treatment of stress urinary incontinence.

@nl

type

label

Duloxetine versus placebo in the treatment of stress urinary incontinence.

@en

Duloxetine versus placebo in the treatment of stress urinary incontinence.

@nl

prefLabel

Duloxetine versus placebo in the treatment of stress urinary incontinence.

@en

Duloxetine versus placebo in the treatment of stress urinary incontinence.

@nl

P1433

Q44062087-B9692B23-D699-411F-9760-91C8CC65C002

P1476

Q44062087-59B2A189-9176-4662-B022-38A26DF0108B

P2093

Q44062087-1E1B9A04-E184-46F6-9D34-3AB625CDF5A1

Q44062087-49438ADF-91D8-42E8-AAC5-8353A51ED091

Q44062087-5EAF12C5-14E6-4E64-ACDF-8DA2D248C5AD

Q44062087-9E5E0610-3A20-4519-A8EC-CD3E811EA3DA

Q44062087-F6A2B322-9F20-41B9-9342-CE750D55B088

P304

Q44062087-02910321-152F-4701-BB0E-AE45348D64C1

P31

Q44062087-ADC67492-1CF6-4EC4-8955-E2FB16058D36

P356

Q44062087-EB300825-C71F-4AB2-8923-5F9B2D8D01FF

P407

Q44062087-38E172F8-1BD2-4A8C-BFB9-E4385F232855

P433

Q44062087-8CD7B897-8F69-41FC-8583-BC4D8BFC1F6F

P478

Q44062087-A8DB1224-319E-4E2F-B4AF-DF89263BB7D3

P577

Q44062087-5C8FD31C-6176-4358-B796-31BAE7EEF0F4

P698

Q44062087-E2D488C3-19A0-425E-A167-14A1721EBD14

P921

Q44062087-4E243EE8-2E18-4CA0-B945-098A327D9CCA

P356

MOB.2002.124840

P1433

American Journal of Obstetrics and Gynecology

P1476

Duloxetine versus placebo in the treatment of stress urinary incontinence.

@en

P2093

Duloxetine Urinary Incontinence Study Group

http://www.w3.org/2001/XMLSchema#string

Ilker Yalcin

http://www.w3.org/2001/XMLSchema#string

Norman R Zinner

http://www.w3.org/2001/XMLSchema#string

Peggy A Norton

http://www.w3.org/2001/XMLSchema#string

Richard C Bump

http://www.w3.org/2001/XMLSchema#string

P304

40-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1067/MOB.2002.124840

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

187

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12114886

http://www.w3.org/2001/XMLSchema#string

P921